View Single Post
Old 11-16-2006, 08:13 PM   #5
Margerie
Senior Member
 
Margerie's Avatar
 
Join Date: Aug 2006
Posts: 492
Michelle,Yes, good question. My onc said off-label use should reflect current studies, which is either tykerb + herceptin or tykerb + xeloda. I am electing a second year of herceptin (starts mid-Jan), so if we add tykerb in March, I will have both for 9 months. Assuming the ole heart hangs in, has been fine so far. Maybe go another 3 months to make a year of Tykerb. But that herceptin is going to break the bank. We have had to pay our HUGE deductible three years in a row- not too hot on 4 years. Don't think I want to try xeloda at Stage 3.

Let me know what your onc says.
__________________
Are we there yet?


Dx 10/05 IDC, multi-focal, triple +, 5 nodes+
MRM, 4 DD A/C, 12 weekly taxol + herceptin
rads concurrent with taxol/herceptin
finished herceptin 01/08
ooph, Arimidex, bilateral DIEP reconstruction
NED
Univ. of WA, Seattle vaccine trial '07
Margerie is offline   Reply With Quote